000 01389 a2200397 4500
005 20250515192618.0
264 0 _c20100203
008 201002s 0 0 eng d
022 _a1542-6270
024 7 _a10.1345/aph.1M457
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMarks, Anne-Bérengère
245 0 0 _aSorafenib-induced hepatic encephalopathy.
_h[electronic resource]
260 _bThe Annals of pharmacotherapy
_cDec 2009
300 _a2121 p.
_bdigital
500 _aPublication Type: Case Reports; Letter
650 0 4 _aAntineoplastic Agents
_xadministration & dosage
650 0 4 _aBenzenesulfonates
_xadministration & dosage
650 0 4 _aCarcinoma, Hepatocellular
_xdrug therapy
650 0 4 _aDose-Response Relationship, Drug
650 0 4 _aHepatic Encephalopathy
_xchemically induced
650 0 4 _aHumans
650 0 4 _aLiver Neoplasms
_xdrug therapy
650 0 4 _aMiddle Aged
650 0 4 _aNiacinamide
_xanalogs & derivatives
650 0 4 _aPhenylurea Compounds
650 0 4 _aPyridines
_xadministration & dosage
650 0 4 _aSorafenib
650 0 4 _aTime Factors
700 1 _aGerard, Romain
700 1 _aFournier, Peggy
700 1 _aCoupe, Patrick
700 1 _aGautier, Sophie
773 0 _tThe Annals of pharmacotherapy
_gvol. 43
_gno. 12
_gp. 2121
856 4 0 _uhttps://doi.org/10.1345/aph.1M457
_zAvailable from publisher's website
999 _c19251123
_d19251123